These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 20082658)

  • 1. Early defect of transforming growth factor β1 formation in Huntington's disease.
    Battaglia G; Cannella M; Riozzi B; Orobello S; Maat-Schieman ML; Aronica E; Busceti CL; Ciarmiello A; Alberti S; Amico E; Sassone J; Sipione S; Bruno V; Frati L; Nicoletti F; Squitieri F
    J Cell Mol Med; 2011 Mar; 15(3):555-71. PubMed ID: 20082658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
    Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
    Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rescue of BDNF expression by the thalamic parafascicular nucleus with chronic treatment with the mGluR2/3 agonist LY379268 may contribute to the LY379268 rescue of enkephalinergic striatal projection neurons in R6/2 Huntington's disease mice.
    Wang H; Del Mar N; Deng Y; Reiner A
    Neurosci Lett; 2021 Oct; 763():136180. PubMed ID: 34416343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
    Hebb AL; Robertson HA; Denovan-Wright EM
    Neuroscience; 2004; 123(4):967-81. PubMed ID: 14751289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.
    Kuhn A; Goldstein DR; Hodges A; Strand AD; Sengstag T; Kooperberg C; Becanovic K; Pouladi MA; Sathasivam K; Cha JH; Hannan AJ; Hayden MR; Leavitt BR; Dunnett SB; Ferrante RJ; Albin R; Shelbourne P; Delorenzi M; Augood SJ; Faull RL; Olson JM; Bates GP; Jones L; Luthi-Carter R
    Hum Mol Genet; 2007 Aug; 16(15):1845-61. PubMed ID: 17519223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.
    Seo H; Kim W; Isacson O
    Hum Mol Genet; 2008 Oct; 17(20):3144-53. PubMed ID: 18640989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
    Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
    J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways.
    D'Onofrio M; Cuomo L; Battaglia G; Ngomba RT; Storto M; Kingston AE; Orzi F; De Blasi A; Di Iorio P; Nicoletti F; Bruno V
    J Neurochem; 2001 Aug; 78(3):435-45. PubMed ID: 11483646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes.
    Chou SY; Weng JY; Lai HL; Liao F; Sun SH; Tu PH; Dickson DW; Chern Y
    J Neurosci; 2008 Mar; 28(13):3277-90. PubMed ID: 18367595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.
    Reiner A; Lafferty DC; Wang HB; Del Mar N; Deng YP
    Neurobiol Dis; 2012 Jul; 47(1):75-91. PubMed ID: 22472187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
    Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
    Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabotropic Glutamate Receptor 2/3 Activation Improves Motor Performance and Reduces Pathology in Heterozygous zQ175 Huntington Disease Mice.
    Li SH; Colson TL; Abd-Elrahman KS; Ferguson SSG
    J Pharmacol Exp Ther; 2021 Oct; 379(1):74-84. PubMed ID: 34330748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease.
    García-Martínez JM; Pérez-Navarro E; Xifró X; Canals JM; Díaz-Hernández M; Trioulier Y; Brouillet E; Lucas JJ; Alberch J
    J Neurosci Res; 2007 Sep; 85(12):2756-69. PubMed ID: 17387706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Astrocytes from cortex and striatum show differential responses to mitochondrial toxin and BDNF: implications for protection of striatal neurons expressing mutant huntingtin.
    Saba J; López Couselo F; Turati J; Carniglia L; Durand D; de Laurentiis A; Lasaga M; Caruso C
    J Neuroinflammation; 2020 Oct; 17(1):290. PubMed ID: 33023623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease.
    Schiefer J; Sprünken A; Puls C; Lüesse HG; Milkereit A; Milkereit E; Johann V; Kosinski CM
    Brain Res; 2004 Sep; 1019(1-2):246-54. PubMed ID: 15306259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice.
    Xie Y; Hayden MR; Xu B
    J Neurosci; 2010 Nov; 30(44):14708-18. PubMed ID: 21048129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice.
    Reiner A; Del Mar N; Deng YP; Meade CA; Sun Z; Goldowitz D
    J Comp Neurol; 2007 Dec; 505(6):603-29. PubMed ID: 17948889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
    Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
    J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice.
    Reiner A; Wang HB; Del Mar N; Sakata K; Yoo W; Deng YP
    Brain Res; 2012 Sep; 1473():161-72. PubMed ID: 22820300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.